NCT01817686 - Study of Default Options in Advance Directives | Biotech Hunter

Enrollment

62

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

COPDSevere or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen TherapyIdiopathic Pulmonary FibrosisOther Interstitial Lung Disease Without Curative TherapyCongestive Heart FailureNYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past YearMalignancyAny Stage 3B or 4 Solid Tumor

Interventions

OTHER

Comfort Default AD forms

Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.

OTHER

Life Extension Default AD forms

Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.

OTHER

Standard Default AD forms

Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.

Trial Locations (1)

19104

Philadelphia Veterans Affairs Medical Center, Philadelphia